CDK4 and liposarcoma: Excitingly, palbociclib and its relatives are showing great promise in clinical trials for other solid tumors, including another aggressive sarcoma, dedifferentiated liposarcoma (DDLPS) [25], which frequently harbors amplification of CDK4 (NCT01209598, NCT02897375) [26].